

Ref. No.: WOCK/SEC/SE/2025-26/046

3rd November, 2025

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
--	---

Dear Sir/ Madam,

Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') - Press Release

Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2025.

A copy of the same will also be uploaded on the Company's website www.ockhardt.com

Kindly take the same on record please.

Thanking you,
For **Wockhardt Limited**

Rashmi Mamtura
Company Secretary


Encls: as above

Mumbai, November 3rd, 2025

Wockhardt reports Positive PBT in Q2FY26 - INR 91 crore

FINANCIAL HIGHLIGHTS

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 2nd Quarter Results for Financial Year 2025-26, today.



Profit before tax Rs.91 cr for Q2FY26 as compared to loss of Rs. (-)109 Cr in the previous quarter.

Revenue for Q2FY26 is INR 782 Cr compared to INR 738 Cr in the previous quarter. QoQ growth of 58% in EBITDA in Q2FY26, EBITDA for Q2FY26 of INR 160 Cr compared to INR 101 Cr in the earlier quarter.

Novel Antibiotics:

ZAYNICH®:

Global Phase III clinical study completed

**97% clinical efficacy****20%****Superiority over gold standard Meropenem****64**

mg/L

Breakpoint granted by CLSI, USA

for all major gram negative pathogens family


In September 2025 the Company has made submission of New Drug

Application (NDA) to the U.S. Food and Drug Administration (US FDA) for its novel antibacterial agent WCK 5222, ZAYNICH. The NDA seeks approval for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, with or without concurrent bacteremia caused by Gram-negative bacteria including multidrug-resistant (MDR). In US and EU, more than 8 Million cUTI cases are reported every year, reflecting the global burden of Gram negative infections.

This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company, a momentous achievement for Indian innovation.

- NDA Filing with US FDA completed in September, 2025
- Saudi Arabia BMP (Breakthrough medicines program) designation received from Saudi FDA in Jul'25
- Zaynich manufacturing from European CMOs
- Filing done in India in March, 2025

MIQNAF® NAFITHROMYCIN, approved and launched on May 27 2025, in India



Nafithromycin Phase 3 CABP study published in globally renowned journal LANCET. According to the 2024 Journal Citation Reports® (Clarivate 2025), this journal ranks 10th among 185 journals in the Health Care Sciences and Services category. This publication in a LANCET journal for

97%Success Rate in
Community Acquired
Pneumonia

Ultra Short

3-Day

Treatment

a novel drug discovered in India is a 1st ever event, underlining the quality of this study and the scientific outcomes.

Nafithromycin included in Clinical Infectious Disease Society's official diagnosis and treatment guidelines 2025 as a treatment for CABP caused by resistant pathogens.


EMROK/ EMROK O:

Emrok and Emrok O Included in Clinical Infectious Disease Society's official diagnosis and treatment guidelines Update book 2025 for the treatment of resistant Gram positive infections including MRSA. The book has been authored by leading Infectious Disease consultants with extensive clinical experience across tertiary care centers as well as smaller hospitals. Emrok has been highlighted as a recommended treatment option for Community-acquired Pneumonia (CAP), Severe Skin and Soft Tissue Infections (SSTIs) caused by MRSA, bone and joint infection (BJI) and diabetic foot infection. Additionally, Emrok has been extensively covered in a dedicated chapter on Newer Drugs against Gram-Positive Organisms, where the authors have detailed key aspects such as its mechanism of action, pathogen spectrum, PK/PD characteristics, and breakpoints.



ERTAPENEM-ZIDEACTAM (WCK 6777):


Phase 2 study protocol has been finalized to compare once-a-day (OD) WCK 6777 with three-times-a-day (TID) cefazidime/avibactam in patients with hospitalized cUTI. This study would help identify clinical dose for Phase 3 study. US FDA has already granted a Fast-track designation to WCK 6777 for two indications – cUTI and cIAI.



FOVISCU (WCK 4282):

Enrolment of patients in Phase 2/3 study of WCK 4282 has been completed. A total of 324 hospitalized patients with cUTI including acute pyelonephritis were enrolled in the study. This study compared WCK 4282 with gold standard hospital antibiotic meropenem. The results of this study would form the basis for filing NDA. The clinical data of Phase 3 study would position WCK 4282 as effective drug for the treatment of highly prevalent ESBL infections for which current treatment options - piperacillin/tazobactam and cefoperazone/sulbactam have been compromised due to rising resistance. This situation has led to overdependence on meropenem which has triggered wide spread carbapenem resistance. WCK 4282 would not only provide a reliable 1st line empirical antibiotic for Gram negative infections but would also minimize the usage of meropenem and positively benefit by controlling AMR.

Biosimilar Highlights



- The overall Biotech operations for the quarter stood at INR 154 Crores recording growth of 42% vs Q4 FY 25 and 41% vs Q1 FY26. This robust achievement is fuelled by our Emerging market biotech segment growing at > 50% with accelerated business opportunities and strategic partnerships, new deal

acquisitions from our key markets like Thailand, Egypt, Algeria and Latam. Our Domestic Biotech operations also grew at double digit pace and is poised for decent growth in the future.

- We see significant scale up and advancing our leadership in the Biotech diabetes segment on the back of new partnerships in the Emerging markets and India, entry into new markets like Russia and Malaysia as we commit to offer affordable Insulin globally. Our strength lies in our robust and end to end well integrated Biotech infrastructure. Looking ahead, the upcoming launch of insulin analogs in the coming quarters represents a significant business opportunity, further strengthening our commitment to meeting global diabetes healthcare needs and advancing our leadership in diabetes care.

Business Highlights

India Business stood at Rs.172 crore in Q2FY26 with a growth of 3% compared to the previous year.

UK Business stood at Rs.313 crore in Q2FY26 with a growth of 4% compared to the previous year.

Irish Business stood at Rs.59 crore in Q2FY26 with a growth of 40% compared to the previous year.

New Products Launch:

- 2 Filing and 7 Launches in Wockhardt UK and 2 Filings and 6 Launches in Pinewood
- Biosimilars 7 Filings and 10 Approvals and NCE - 2 Filings & 1 Approval
- EMROK/ EMROK O- Registration has been filed in 9 countries of ROW and other markets

- Approval received for EMROK O for Uganda and for EMROK injection in August, 2025.

Intellectual Property Update:

- 7 patents were filed during the quarter ended 30th September 2025 and the cumulative filings till date are 3285.
- The company was granted 5 patents during the quarter and now holds 858 patents.

Financial Performance:

Particulars	Q2 FY26	Q2 FY25	Q1 FY26	H1 FY26	H1 FY25
	Jul - Sep 2025	Jul - Sep 2024	Apr - Jun 2025	Apr - Sep 2025	Apr - Sep 2024
Total Revenue	782	818	738	1,520	1,565
EBITDA before R&D	194	167	128	322	293
EBITDA % to Sales	24.8%	20.4%	17.4%	21.2%	18.7%
R&D	34	28	27	61	54
R&D % to Sales	4.4%	3.4%	3.7%	4.0%	3.5%
EBITDA	160	139	101	261	239
EBITDA Margins %	20.5%	17.0%	13.7%	17.2%	15.3%
Exceptional Items #	-	-	(97)	(97)	-
PBT	91	(9)	(109)	(18)	(15)
Profit After Tax	82	(16)	(108)	(26)	(32)
PAT Margins %	10.5%	-2.0%	-14.6%	-1.7%	-2.0%

Exceptional Items: Goodwill impaired as Morton Grove Pharmaceuticals Inc., a step down subsidiary of Wockhardt, entered voluntary liquidation proceedings under Chapter 7 of the US Bankruptcy Code, effective July 11, 2025

About Wockhardt

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.



PRESS RELEASE



Wockhardt Limited

Registered Office:
D-4, MIDC, Chikalthana
Chhatrapati Sambhajinagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720

Wockhardt is employing around ~2900 people and 27 nationalities with presence in UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India and UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in Europe and India, with 79% of its global revenues coming from international businesses.